Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Carmen Black Parker, MD, Amanda Calhoun, MD, MPH, Ambrose H. Wong, MD, MSEd, Larry Davidson, PhD, and Charles Dike, MBChB, MPH
Psychiatric emergencies, coping stress reactions, and iatrogenic injuries are not responded to with the same vigor as acute medical decompensation. That needs to change.
AMA J Ethics. 2020;22(11):E956-964. doi:
10.1001/amajethics.2020.956.
This article examines conceptual limitations of extant accounts of palliative psychiatry, with a focus on obligations to distinguish among and clearly formulate goals of care.
AMA J Ethics. 2023;25(9):E710-717. doi:
10.1001/amajethics.2023.710.
Pamela B. Teaster, PhD, MA, MS and Al O. Giwa, LLB, MD, MBA, MBE
Since ageism contributes to global mental health inequity among older people, responding to their needs should be a clinical, ethical, and policy priority.
AMA J Ethics. 2023;25(10):E765-770. doi:
10.1001/amajethics.2023.765.